DANIEL SHULL: Open Payments
NPI 1508931650 · ZIONSVILLE, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,236 in 72 payments from 21 companies in 2025. Trend: 2023 $2,147 · 2024 $1,470 · 2025 $1,236
Food & beverage: $1,204Education: $33
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 18 | $257 |
| ABBVIE INC. | 12 | $144 |
| Lilly USA, LLC | 8 | $127 |
| Amgen Inc. | 4 | $67 |
| ABIOMED | 1 | $57 |
| Teva Pharmaceuticals USA, Inc. | 3 | $55 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $54 |
| Otsuka America Pharmaceutical, Inc. | 2 | $50 |
| AstraZeneca Pharmaceuticals LP | 2 | $50 |
| Viatris Specialty LLC | 2 | $49 |
Products named: Ozempic, MOUNJARO, VRAYLAR, AUSTEDO XR, Kerendia, REXULTI, FARXIGA, YUPELRI.
Industry payments across IN — which companies pay providers there.
